ZA200703955B - Enteric coated bead comprising ixabepllone, and preparation thereof - Google Patents

Enteric coated bead comprising ixabepllone, and preparation thereof

Info

Publication number
ZA200703955B
ZA200703955B ZA200703955A ZA200703955A ZA200703955B ZA 200703955 B ZA200703955 B ZA 200703955B ZA 200703955 A ZA200703955 A ZA 200703955A ZA 200703955 A ZA200703955 A ZA 200703955A ZA 200703955 B ZA200703955 B ZA 200703955B
Authority
ZA
South Africa
Prior art keywords
ixabepllone
preparation
enteric coated
coated bead
bead
Prior art date
Application number
ZA200703955A
Other languages
English (en)
Inventor
Ullah Ismat
Wiley Gary James
Original Assignee
Bristol Meyers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Meyers Squibb Co filed Critical Bristol Meyers Squibb Co
Publication of ZA200703955B publication Critical patent/ZA200703955B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ZA200703955A 2004-11-18 2007-05-16 Enteric coated bead comprising ixabepllone, and preparation thereof ZA200703955B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62897004P 2004-11-18 2004-11-18

Publications (1)

Publication Number Publication Date
ZA200703955B true ZA200703955B (en) 2008-08-27

Family

ID=35976527

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703955A ZA200703955B (en) 2004-11-18 2007-05-16 Enteric coated bead comprising ixabepllone, and preparation thereof

Country Status (25)

Country Link
US (1) US20060153917A1 (https=)
EP (2) EP1817013B1 (https=)
JP (1) JP2008520696A (https=)
KR (1) KR20070084325A (https=)
CN (1) CN101083978A (https=)
AR (1) AR052142A1 (https=)
AT (1) ATE397442T1 (https=)
AU (1) AU2005306464A1 (https=)
BR (1) BRPI0518286A2 (https=)
CA (1) CA2588400A1 (https=)
DE (1) DE602005007376D1 (https=)
DK (1) DK1817013T3 (https=)
ES (1) ES2306278T3 (https=)
HR (1) HRP20080349T3 (https=)
IL (1) IL183116A0 (https=)
MX (1) MX2007005763A (https=)
NO (1) NO20072388L (https=)
PE (1) PE20061058A1 (https=)
PL (1) PL1817013T3 (https=)
PT (1) PT1817013E (https=)
RU (1) RU2349319C1 (https=)
SI (1) SI1817013T1 (https=)
TW (1) TW200631609A (https=)
WO (1) WO2006055740A1 (https=)
ZA (1) ZA200703955B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101091725A (zh) 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
ME02464B (me) 2010-03-12 2017-02-20 Genzyme Corp Kombinovana terapija za lečenje raka dojke
WO2012047802A2 (en) * 2010-10-01 2012-04-12 The Johns Hopkins University Systems and methods for high-throughput microfluidic bead production
AU2012214553B2 (en) 2011-02-11 2015-07-09 Sociétés des Produits Nestlé S.A. Multiparticulate L-menthol formulations and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
ES2706152T3 (es) 2013-04-23 2019-03-27 Zx Pharma Llc Composición entérica de múltiples partículas revestida con subrevestimiento proteico

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
DK1186606T4 (da) * 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
JP4090529B2 (ja) * 1996-01-24 2008-05-28 フロイント産業株式会社 乳糖の球形粒及びその製造方法
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6251911B1 (en) * 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
DK1367057T3 (da) * 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
PT975638E (pt) * 1997-02-25 2002-12-31 Biotechnolog Forschung Mbh Gbf Epothilons modificados nas cadeias laterais
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
DE69925293T2 (de) * 1998-10-01 2006-01-26 Powderject Research Ltd. Sprühbeschichtete mikropartikel für nadellose spritzen
YU59001A (sh) * 1999-02-18 2005-07-19 Schering Ag. 16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena
BR0008379A (pt) * 1999-02-22 2002-09-24 Biotechnolog Forschung Gmbh Epotilonas modificadas em c-21
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
IL149030A0 (en) * 2000-08-09 2002-11-10 Panacea Biotec Ltd Pharmaceutical compositions containing rifampicin, isoniazid or combinations thereof
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EP1319011B1 (de) * 2000-09-22 2012-12-05 Helmholtz-Zentrum für Infektionsforschung GmbH Triazolo-epothilone
EP1191127B1 (de) 2000-09-26 2004-10-13 Enthone-OMI (Deutschland) GmbH Verfahren zur selektiven Metallisierung dielektrischer Materialien
IL156580A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
HU229349B1 (en) * 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
PL363363A1 (en) * 2001-02-20 2004-11-15 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
BR0207487A (pt) * 2001-02-20 2004-08-10 Brystol Myers Squibb Company Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
MXPA03010909A (es) * 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
JP4645789B2 (ja) * 2001-06-18 2011-03-09 Ｊｓｒ株式会社 ネガ型感放射線性樹脂組成物
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
SI1483251T1 (sl) * 2002-03-12 2010-03-31 Bristol Myers Squibb Co C cian epotilonski derivati
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en) * 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
EP1539111A1 (en) * 2002-08-05 2005-06-15 DSM IP Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
AU2003279911A1 (en) * 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Therapeutic formulations
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof

Also Published As

Publication number Publication date
ES2306278T3 (es) 2008-11-01
SI1817013T1 (sl) 2008-12-31
PT1817013E (pt) 2008-08-07
MX2007005763A (es) 2007-07-20
EP1958625A1 (en) 2008-08-20
AU2005306464A1 (en) 2006-05-26
DK1817013T3 (da) 2008-10-13
DE602005007376D1 (de) 2008-07-17
US20060153917A1 (en) 2006-07-13
CN101083978A (zh) 2007-12-05
WO2006055740A1 (en) 2006-05-26
PL1817013T3 (pl) 2009-01-30
HRP20080349T3 (hr) 2009-01-31
IL183116A0 (en) 2007-09-20
RU2349319C1 (ru) 2009-03-20
AR052142A1 (es) 2007-03-07
NO20072388L (no) 2007-06-14
EP1817013B1 (en) 2008-06-04
ATE397442T1 (de) 2008-06-15
CA2588400A1 (en) 2006-05-26
JP2008520696A (ja) 2008-06-19
HK1106713A1 (en) 2008-03-20
EP1817013A1 (en) 2007-08-15
KR20070084325A (ko) 2007-08-24
BRPI0518286A2 (pt) 2008-11-11
TW200631609A (en) 2006-09-16
PE20061058A1 (es) 2006-10-13

Similar Documents

Publication Publication Date Title
IL183018A0 (en) Staibilized individually coated ramipril particles, compositions and methods
GB2411452C (en) Flat and collapsible mouse
EP1824796A4 (en) PROTEIN SKELETONS AND USES THEREOF
IL180682A0 (en) N-hydroxamide derivatives, their preparation and use
EP1784163A4 (en) NANOEMULSION, USE THEREOF AND PROCESS FOR PREPARING THE SAME
IL181069A0 (en) Sulphonamide derivatives , their preparation and their therapeutic application
IL182554A0 (en) Anti-addl antibodies and uses thereof
IL209494A (en) Formulations of insulin oligomeric monoconogues and their use
ZA200706254B (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
SG116670A1 (en) Termination coating.
ZA200703955B (en) Enteric coated bead comprising ixabepllone, and preparation thereof
IL178277A0 (en) Irta-5 antibodies and their uses
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
IL181569A0 (en) Biotinylated hexadecasaccharides, preparation and use thereof
TWI350287B (en) Acylaminothiazole derivatives, their preparation and their therapeutic application
GB0501783D0 (en) Catalysts and preparation method
IL180365A0 (en) Carboranylporphyrins and uses thereof
TWI367222B (en) Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
GB0403491D0 (en) Polypeptides, methods and means
IL177759A0 (en) Cospeptin, cosmedin and their uses
EP1813671A4 (en) SOLUBLE PROTEIN AND USE THEREOF
IL181903A0 (en) Irta-4 antibodies and their uses
TWI340642B (en) Acylaminothiazole derivatives, preparation and therapeutic application thereof
EP1833989A4 (en) VIRUS PREPARATIONS AND METHODS
HU2925U (en) Coated curd-dessert